At Plus Therapeutics, advancing treatment for patients with recurrent glioblastoma (GBM) requires collaboration with some of the brightest minds in brain cancer research and neurosurgery. Today, we’re proud to feature one of our esteemed RESPECT-GBM Principal Investigators: Toral Patel, M.D.
Dr. Patel is a board-certified neurosurgeon specializing in brain tumor surgery and currently serves as the Director of the Brain Tumor Program at UT Southwestern Medical Center. She brings deep clinical insight and compassionate patient care to her work, along with a strong research background focused on improving treatment outcomes for patients with malignant brain tumors.
Her exceptional contributions to the field have earned her numerous accolades, including consistent recognition on D Magazine’s “Best Doctors” list since 2018. Dr. Patel is also a dedicated member of leading professional organizations such as:
-
The Society for Neuro-Oncology (SNO)
-
The Congress of Neurological Surgeons (CNS)
-
The American Association of Neurological Surgeons (AANS)
Her expertise and leadership are instrumental in guiding the RESPECT-GBM Phase 2 clinical trial, which is currently enrolling patients with recurrent glioblastoma. This trial is evaluating an innovative, targeted radiotherapeutic designed to deliver treatment directly to GBM tumor sites with precision.
If you or someone you know may be eligible and is seeking new treatment options for recurrent GBM, we invite you to learn more about the trial and Dr. Patel’s involvement here: RESPECT-GBM Clinical Trial Information
Or reach out to our team at respect@plustherapeutics.com to explore participation.
#RESPECTGBM #Glioblastoma #BrainTumor #BrainCancerAwareness #ClinicalTrials #Oncology #CancerResearch #BrainTumorStrong #Neurosurgery #GoGrayInMay #GrayMay #BTAM #BCAM #SNO #CNS #AANS #PlusTherapeutics #PSTV
Recent Comments